Therapeutic Efficacy Monitoring
Therapeutic Efficacy Monitoring - Related Videos
17:16
Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring
0 Views •
Cited by 4 •
2010
Bioimaging methods used to assess cell biodistribution of nanoparticles are applicable for therapeutic and diagnostic monitoring of nanoformulated compounds. The methods described herein are sensitive and specific when assessed by histological coregistration. The methodologies provide a translational pathway from rodent to human applications.
09:01
Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
0 Views •
Cited by 9 •
2015
We describe methods for longitudinal monitoring of the efficacy of therapeutics for the treatment of colonic pathologies in mice using a rigid endoscope. This protocol can be readily used for the characterization of the therapeutic response of an individual tumor in live mice and also for monitoring potential disease relapse.
09:51
Monitoring Changes in the Intracellular Calcium Concentration and Synaptic Efficacy in the Mollusc Aplysia
0 Views •
Cited by 4 •
2012
We demonstrate how changes in the intracellular free calcium concentration and synaptic efficacy can be simultaneously monitored in a ganglion preparation of Aplysia. We image intracellular calcium using a fluorescent dye, Calcium Orange, and induce and monitor synaptic transmission with sharp (intracellular) electrodes.
01:29
Therapeutic Drug Monitoring: Affecting Factors
0 Views •
2025
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
06:12
Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model
0 Views •
Cited by 5 •
2015
Here the method to establish a syngeneic mouse model of orthotopic bladder tumour to evaluate the anti-tumour efficacy of the bacterial protein HP-NAP is described.
FAQs
Target engagement measurements show whether a therapy reaches and affects its intended biological target, while biomarker levels and physiological responses indicate downstream activity. Patient outcomes add evidence about clinical relevance. Considering these layers together helps distinguish a treatment that produces an expected biological change from one that shows little or no measurable effect, even before final outcomes are available.
Comparing measurements over time helps reveal whether biological or physiological changes persist, improve, or fail to align with predefined treatment goals. A single measurement may not show whether an observed response represents meaningful benefit or inadequate response. Repeated assessments therefore support better decisions about continuing, changing, or stopping therapy.
Predefined treatment goals provide the reference point for interpreting monitoring data. Target engagement, biomarker levels, physiological responses, and patient outcomes can be compared with those goals rather than viewed in isolation. This framework makes it easier to identify inadequate response and supports evidence-based decisions about whether an intervention should continue or change.
A practical assessment sequence sets treatment goals, collects measurements relevant to biological or clinical effect, compares results over time, and interprets them against the intended outcome. Depending on the findings, monitoring can inform continuation, modification, or discontinuation of therapy. This structured workflow turns repeated measurements into actionable treatment decisions.
Engineered biosensors can generate quantitative measurements, while diagnostic platforms and imaging systems offer additional ways to observe treatment-related effects. Computational models can contribute to organizing and interpreting these data across time. Together, these technologies support more individualized treatment assessment and provide time-resolved information for dose and intervention decisions.
Monitoring data support personalized treatment by showing how biological, physiological, and clinical responses correspond to treatment goals. The findings can guide dose and intervention decisions, help determine whether therapy should continue, change, or stop, and contribute to the development of safer, more effective therapies. This connects treatment assessment with both clinical decisions and bioengineering research.